Denise Peterson

Time to spotlight folks doing great work in R&D strategy and trial design, including excellence in AI, diversity, RWE, and patient-facing technology. Nominate them for the Citeline Awards; deadline is now March 1. ow.ly/34jn50QFEfU

A holiday gift for anyone wondering what I was up to for @PharmaScrip at #ASH24 a few weeks ago: one of my long reads about what’s happening in sickle cell disease is free to read without a subscription. scrip.citeline.com/SC149532/Hemat…

@PharmaPinkSheet previously reported on sponsor's plans to contest withdrawal - get caught up here pink.pharmaintelligence.informa.com/PS148683/Accel…

My comrade Brenda Sandburg several years ago profiled pioneering photojournalist Betty Steele, who died recently. Here’s an short – and wonderful – clip of Brenda interviewing Betty. Inspiring.

Join host @jrovner and panelists @shefalil, @SarahKarlin, and @AliceOllstein for a new health-packed ep. of #WTHealth! This week's discussion includes reproductive health, drug pricing, legislation for organ transplants, and more! kffhealthnews.org/news/podcast/w…

My TrialScope colleagues are benchmarking how biopharmas balance clinical trial reporting compliance/transparency with redacting sensitive company & patient data. If you’re involved in this area, help us out by taking this brief confidential survey: bit.ly/44dN5yH

More on the House Republican drug shortage bill this came from, from me last week: pink.pharmaintelligence.informa.com/PS148621/All-C…

Thomas Wicks, a Citeline colleague & trial transparency SME, is benchmarking how pharma is balancing transparency with needs to redact or anonymize some data. Help us out with our survey. #clinicaltrials #redaction #transparency surveymonkey.com/r/CCI_LI

A handy, quick reference for tracking industry lawsuits over the IRA's drug price negotiation provisions pink.pharmaintelligence.informa.com/articles/2023/…

Saudi FDA’s membership to PIC/s means that it can become a reference authority for inspecting pharmaceutical factories, reports @ScripFrancesca pink.pharmaintelligence.informa.com/PS148342/Saudi…

Wow - only 6 voting members on panel, 2 of whom are regular members of the PCNSDAC. In all my many many years of covering adcomms have never seen a panel that small.

Our first day #BIO2023 notefrom from me, @ScripMandy and Kevin Grogan. pink.pharmaintelligence.informa.com/PS148324/BIO-N…

@VikasReports @BioPharmaJosh love this!

@BioPharmaJosh - days of our Boston meetings and all the industry chatter :)

(2/2) And here is @PinkSheetSutter's look at Pepaxto from the FDA perspective ... #PinkSheet #pharma: pink.pharmaintelligence.informa.com/PS148001/Statu…

(1/2) An interesting look at the saga of Pepaxto from our @ScripFrancesca and @PinkSheetSutter today. This is Francesca's look at the EMA perspective ... #pinksheet #pharma: Oncopeptides’ Melflufen: Same Data, Different Conclusions From EMA, US FDA pink.pharmaintelligence.informa.com/articles/2023/…

More supplemental filings from me and @SarahKarlin ... #pinksheet #pharma: Supplemental Filings: Pink Sheet Notebook On Disease Lobbying, Dan Leonard’s Next Act, And More pink.pharmaintelligence.informa.com/articles/2023/…

Our quick hit on the Makena situation pink.pharmaintelligence.informa.com/articles/2023/…

Our take on yesterday's big neurology news from @PinkSheetSutter ... #pinksheet #pharma: @US_FDA Neuroscience Office Director Billy Dunn Departs As Agency Faces New Review Challenges pink.pharmaintelligence.informa.com/articles/2023/…

My analysis of the new OPT org chart ... #Pinksheet #Pharma: CBER’s New Home For Gene Therapies: OTAT Changes To OTP But Leadership Questions Remain pink.pharmaintelligence.informa.com/articles/2023/…

“We have these big societal issues and the decision about an individual product is like the tip of the spear of something that needs context,” @US_FDA's Robert Califf says about use of adcomms @SarahKarlin pink.pharmaintelligence.informa.com/articles/2023/…